| 1 |
Development of osteoarthritis drug with a novel mechanism of inflammasome blockade |
| Small Molecules |
Osteoarthritis |
Caspase |
Preclinical |
Innovo Therapeutics, Inc. |
RS-2023-00282719 |
|
| 2 |
Clinical Trial Development of Small Molecule Inhibitor for Progeria Treatment: Progerinin |
| Small Molecules |
Progeria syndromes |
Progerin PPI |
Phase 2 |
PRG S&Tech Inc. |
RS-2023-00258708 |
|
| 3 |
Development of EFL.1101, a topical anticholinergic agent, for the Treatment of Hyperhidrosis |
| Small Molecules |
Hyperhidrosis |
Muscarinic M3 |
Preclinical |
eFlask |
RS-2023-00258121 |
|
| 4 |
A novel GFRA1 agonist, JW0061 development for androgenic alopecia treatment |
| Small Molecules |
Androgenetic alopecia |
GFRA1 |
Preclinical |
JW Pharmaceutical |
RS-2023-00217372 |
|
| 5 |
Development of PROTAC-based **** degrader for promoting cartilage regeneration in osteoarthritis |
| Small Molecules |
Osteoarhtritis |
Tankyrase |
Hit |
Seoul National University |
RS-2023-00217266 |
|
| 6 |
Development of multi-functioning lead compounds for lymphedema |
| Small Molecules |
Lymphedema |
Nrf2 |
Lead |
RAPPELER |
HN22C0095 |
|
